Corona Remedies Ltd

CORONA

Watchlist

AI Mode

‌

Market Cap

₹ 8,790 Cr

P/E

58.61

‌

‌
‌

‌

‌
‌

Investment Checklist

How to read checklist?

Performance

STEADY PERFORMER

Valuation

OVERVALUED

Growth

STABLE

Profitability

MODERATE MARGIN

Technicals

—

Risk

MODERATE RISK

Investment Checklist

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

Price

PE Ratio

Price

‌

Overview

Sector

Pharmaceuticals

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln M/S

Market Cap

8,790 Cr

Volatility

—

P/E Ratio

58.6

Industry P/E

30.8

PEG Ratio

0.9

P/B Ratio

14.5

52W High

1,499.00

52W Low

1,412.65

Sales CAGR

17.94%

—

10Y

—

Profit CAGR

65.12%

—

10Y

—

ROE

TTM

—

21.70%

17.84%

10Y

—

ROCE

TTM

—

26.04%

21.76%

10Y

—

Technicals

‌

Forecasts

Peers

Symbol	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
BLUEJET	550.00	9,537 Cr	27.07	7.59	0.22	28.06	37.35	23.07
CORONA	1437.20	8,790 Cr	58.61	14.50	0.51	0.00	0.00	—
STAR	870.85	8,005 Cr	18.36	2.90	0.46	14.42	14.96	6.33
SUDEEPPHRM	669.10	7,557 Cr	54.44	12.87	0.00	—	—	0.00
AARTIPHARM	760.85	6,852 Cr	28.58	3.35	0.66	11.72	12.99	7.34
FDC	422.50	6,852 Cr	30.39	2.82	1.19	9.27	12.51	7.81
AKUMS	422.30	6,652 Cr	21.63	2.11	0.00	10.07	8.99	6.27

Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

AI Mode

Consolidated Quarterly Results (in ₹ Crores)

Total Figures

QoQ Changes

Total Figures

	Jun 2025
Sales	347
Expenses	277
Operating Profit	70
OPM %	20.14
Other Income	1.82
Interest	1.99
Depreciation	8.92
Profit Before Tax	61
Tax %	23.89
Net Profit	46
EPS in Rs	—

Consolidated Profit Loss (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2023	Mar 2024	Mar 2025
Sales	884	1,014	1,196
Expenses	756	860	956
Operating Profit	128	155	240
OPM %	14.48	15.25	20.06
Other Income	7.28	6.46	6.32
Interest	4.27	14	11
Depreciation	20	28	37
Profit Before Tax	111	118	199
Tax %	23.41	23.61	24.73
Net Profit	85	91	149
EPS in Rs	—	—	—
Dividend Payout %	19.01	25.00	29.92

Consolidated Balance Sheet (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2023	Mar 2024	Mar 2025
Equity Capital	61	61	61
Reserves	347	419	545
Borrowings	28	159	86
Other Liabilities	159	191	237
Total Liabilities	595	831	930
Fixed Assets	185	384	370
CWIP	65	121	186
Investments	31	26	26
Other Assets	314	301	348
Total Assets	595	831	930

Consolidated Cash Flows (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity	103	157	190
Cash from Investing Activity	-50	-267	-84
Cash from Financing Activity	-45	99	-107
Net Cash Flow	7.71	-11	0.07

Shareholdings

Shareholding History

Quarterly

Yearly

Quarterly

	Apr 2025	Dec 2025
Promoters	72.50%	69.00%
FIIs	0.00%	1.04%
DIIs	27.50%	3.65%
Public	0.00%	26.32%
Total Shareholders	9	1,59,545

Market Transactions

Date	Party	Category	Type	Avg Price (₹)	Total Value (₹)	Quantity	Percent Traded
Dec 15, 2025	Marwadi chandarana intermedia...	Bulk	Buy	1,463.35	52.98 Cr	3,62,031	0.59
Dec 15, 2025	Junomoneta finsol private lim...	Bulk	Buy	1,459.32	46.41 Cr	3,18,037	0.52
Dec 15, 2025	Invesco mutual fund	Bulk	Buy	1,434.20	100.39 Cr	7,00,000	1.14
Dec 15, 2025	Invesco mutual fund	Bulk	Buy	1,457.42	141.16 Cr	9,68,573	1.58
Dec 15, 2025	Junomoneta finsol private lim...	Bulk	Sell	1,460.34	45.17 Cr	3,09,284	0.50
Dec 15, 2025	Marwadi chandarana intermedia...	Bulk	Sell	1,455.18	53.05 Cr	3,64,531	0.59

Projection

Actions

Action Type

‌
‌

Announcements

Last 7 days

Newest

Sentiment

Regulatory Filing

19 hours ago

Key Managerial Personnel Authorized for SEBI Disclosures

CORONA Remedies Limited has intimated the authorized Key Managerial Personnel for determining materiality of events as per SEBI regulations.

Regulatory Filing

19 hours ago

Code of Practices for Insider Trading

CORONA Remedies Limited has adopted a Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information under SEBI regulations.

Documents

Presentations

Concalls

Reports

Presentations

No documents found!

AI Mode

Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.

AI Mode

Peers

Symbol	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
BLUEJET	550.00	9,537 Cr	27.07	7.59	0.22	28.06	37.35	23.07
CORONA	1437.20	8,790 Cr	58.61	14.50	0.51	0.00	0.00	—
STAR	870.85	8,005 Cr	18.36	2.90	0.46	14.42	14.96	6.33
SUDEEPPHRM	669.10	7,557 Cr	54.44	12.87	0.00	—	—	0.00
AARTIPHARM	760.85	6,852 Cr	28.58	3.35	0.66	11.72	12.99	7.34
FDC	422.50	6,852 Cr	30.39	2.82	1.19	9.27	12.51	7.81
AKUMS	422.30	6,652 Cr	21.63	2.11	0.00	10.07	8.99	6.27

Overview

Sector

Pharmaceuticals

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln M/S

Market Cap

8,790 Cr

Volatility

—

P/E Ratio

58.6

Industry P/E

30.8

PEG Ratio

0.9

P/B Ratio

14.5

52W High

1,499.00

52W Low

1,412.65

Sales CAGR

17.94%

—

10Y

—

Profit CAGR

65.12%

—

10Y

—

ROE

TTM

—

21.70%

17.84%

10Y

—

ROCE

TTM

—

26.04%

21.76%

10Y

—